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Abstract
Background: Gilbert syndrome is caused by defects in bilirubin UDP-glucuronosyltransferase (UGT1A1). The most 
common variation believed to be involved is A(TA)7TAA. Although several polymorphisms have been found to link 
with A(TA)7TAA, the combined effect of regulatory polymorphisms in the development of Gilbert syndrome remains 
unclear.
Methods: In an analysis of 15 patients and 60 normal subjects, we detected 14 polymorphisms and nine haplotypes in 
the regulatory region. We classified the 4-kbp regulatory region of the patients into: the TATA box including A(TA)7TAA; 
a phenobarbital responsive enhancer module including c.-3275T>G; and a region including other ten linked 
polymorphisms. The effect on transcription of these polymorphisms was studied.
Results: All haplotypes with A(TA)7TAA had c.-3275T>G and additional polymorphisms. In an in-vitro expression study 
of the 4-kbp regulatory region, A(TA)7TAA alone did not significantly reduce transcription. In contrast, c.-3275T>G 
reduced transcription to 69% of that of wild type, and the linked polymorphisms reduced transcription to 88% of wild 
type. Transcription of the typical regulatory region of the patients was 56% of wild type. Co-expression of constitutive 
androstane receptor (CAR) increased the transcription of wild type by a factor of 4.3. Each polymorphism by itself did 
not reduce transcription to the level of the patients, however, even in the presence of CAR.
Conclusions: These results imply that co-operation of A(TA)7TAA, c.-3275T>G and the linked polymorphisms is 
necessary in causing Gilbert syndrome.
Background
The elimination pathway of bilirubin in humans is cata-
lyzed exclusively by bilirubin UDP-glucuronosyltrans-
ferase (UGT1A1) [1]. Gilbert syndrome is a mild
hereditary unconjugated hyperbilirubinemia without
liver dysfunction or hemolytic anemia. It is caused by
defects of UGT1A1 and is one of the most prevalent con-
genital metabolic disorders; Gilbert syndrome is found
clinically in 3-10% of the population [2-5].
The UGT1A1 gene (UGT1A1) has the TATA box and a
phenobarbital responsive enhancer module (gtPBREM)
in its regulatory region [6,7]. The wild type of TATA box
has six repeats of TA, and is conventionally written as
A(TA)6TAA [6]. The gtPBREM is an important enhancer
module of UGT1A1, comprising a region of 290-bp. It is
located approximately 3.5 kbp upstream from the coding
region and works in the presence of nuclear receptors,
such as constitutive androstane receptor (CAR) [7].
Three variations are the most common polymorphisms
in patients with Gilbert syndrome: the TA-insertion (c.-
53TA[8]) in the TATA box, written as A(TA)7TAA; c.-
3275T>G in gtPBREM; and c.211G>A (p.G71R) in exon 1
[8-11]. In previous reports, c.-3275T>G has been written
as c.-3279T>G [12]. In the present report we adopted the
nucleotide sequence of UGT1A1  revealed in GenBank
Accession No. NG_002601, based on our gene analysis.
A(TA)7TAA is found in all ethnic groups, and its fre-
quency is 0.36-0.40 in Caucasians, 0.35-0.43 in Africans
and 0.15 in Japanese [11-15]. Most Caucasians and Afri-
cans with Gilbert syndrome have homozygous
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A(TA)7TAA [11]. Consequently, A(TA)7TAA is believed
to be the main cause of Gilbert syndrome.
UGT1A1 activity in patients with Gilbert syndrome
was about 30% of normal, based on studies involving
human liver samples [16-18]. In subsequent studies using
human liver samples of homozygous A(TA)7TAA,
UGT1A1 enzyme activity was 48% of wild type, and the
expression level of UGT1A1 protein was 42-50% of wild
type [18-20]. A(TA)7TAA reportedly has only one-third
of the transcriptional activity of wild type, based on a
gene expression study with the regulatory region from c.-
546 to c.-4 [11]. No statistically significant difference in
activity between A(TA)6TAA and A(TA)7TAA was
detected in our own earlier study, however, using six dif-
ferent lengths of regulatory region varying from 111 to
3188-bp in length [21]. Also, other groups reported that
transcriptional activity was not so drastically reduced by
A(TA)7TAA (to 70-86% of wild type, not by one-third)
[14,22].
The frequency of c.-3275T>G in gtPBREM is 0.26 in
Japanese, 0.47 in Caucasians and 0.85 in African-Ameri-
cans [12,23]. We found that all patients with Gilbert syn-
drome having homozygous A(TA)7TAA were also
homozygous for c.-3275T>G, and we suggested that a
combined effect of these polymorphisms on transcription
is essential to the syndrome [24]. Furthermore, the c.-
3152G>A and c.-364C>T polymorphisms, as well as c.-
3275T>G, were recently found to link with A(TA)7TAA
[12,23], and numerous single nucleotide polymorphisms
(SNPs) of UGT1A1 were also reported on GeneSNPs [25].
To determine the role of the regulatory polymorphisms in
Gilbert syndrome, we first analyzed haplotypes of the
patients and normal subjects. Based on the results, the
transcriptional activity of a continuous 4-kbp regulatory
region was studied in the presence and absence of CAR.
Methods
Sequencing of the UGT1A1 transcriptional regulatory 
region
The upstream region of UGT1A1 were analyzed in a ran-
dom population of 50 Japanese subjects and in four Japa-
nese with Gilbert syndrome having homozygous
A(TA)7TAA, as well as in ten healthy normal Caucasians
and 11 unrelated Caucasians with Gilbert syndrome; all
gave informed consent. The study was approved by the
ethics committee of Shiga University of Medical Science.
We amplified the regulatory region as four separate DNA
fragments, using the polymerase chain reaction (PCR).
Prime Star HS (TaKaRa BIO INC., Shiga, Japan) was used
for PCR of fragment 1 (c.-3559 to c.-2614). Ex Taq
(TaKaRa BIO INC) was used for PCR of fragment 2 (c.-
2670 to c.-883), fragment 3 (c.-950 to c.-314) and frag-
ment 4 (c.-446 to c.879 + 78). The D buffer of a PCR
Optimizer Kit (Invitrogen Corporation, Carlsbad, CA)
was used instead of the attached buffer of Ex Taq in the
P C R  o f  f r a g m e n t  3 .  P C R  p r o d u c t s  w e r e  s e q u e n c e d
directly using an ABI PRISM® Big Dye® Terminator v1.1
Cycle Sequencing Kit (Applied Biosystems, Foster City,
CA). Tables -A1-A and -D1-D show all primers and con-
ditions used in this study.
Construction of expression vectors
To study the effect of the TATA box, gtPBREM, and the
other polymorphisms in the regulatory region, we con-
structed luciferase expression vectors including the regu-
latory regions with differing combinations of these
polymorphisms. We also constructed a CAR expression
vector, to investigate the effect of CAR on transcription of
the regulatory region with gtPBREM.
Cloning of the regulatory region in two separate DNA 
fragments
Two types of genomic DNA were chosen to construct
expression vectors. One is a Gilbert-syndrome type from
a Japanese patient with Gilbert syndrome having
homozygous A(TA)7TAA. The other is wild type from a
normal subject having identical sequence, reported in
GenBank Accession No. NG_002601. The distal region
(c.-4076 to c.-1945) and proximal region (c.-2483 to
c.247) were amplified with PCR, using TaKaRa LA Taq®
Hot Start Version (TaKaRa BIO INC) (Table -B1-B). The
PCR products were cloned into a pCR®-XL-TOPO® vector
with a TOPO XL PCR cloning kit (Invitrogen Corpora-
tion), and the entire regions involved were checked by
sequencing so as to eliminate any mistakes arising in the
PCR amplification (Table -E1-E).
Construction of expression vectors
Restriction sites for ligation into an expression vector
were introduced into the proximal and distal regulatory
regions by PCR of the cloned regulatory region, using
PCR primers with the restriction sites (Table -C1-C).
Each PCR product (proximal; c.-2323 to c.-1: distal; c.-
4076 to c.-1945) was inserted into the PCR®-XL-TOPO®
vector. PGV-B2 expression vectors (TOYO B-Net CO.,
LTD, Tokyo, Japan) having wild-type or Gilbert-syn-
drome-type continuous 4-kbp regulatory region (c.-4076
to c.-1) were constructed by restriction and ligation using
a Ligation-Convenience Kit (NIPPON GENE CO., LTD.,
Tokyo, Japan), as listed in Figure 1: Vectors No.1 and 2 are
wild and Gilbert-syndrome types, respectively.
We found that the typical region between gtPBREM
and A(TA)7TAA of the patient included ten linked poly-
morphisms, c.-3152G>A, c.-2951A>G, c.-2743T>C, c.-
2737T>C, c.-2726G>A, c.-2724AT[8], c.-2473T>G, c.-
1352A>C, c.-689A>C and c.-364C>T (Table 2). The effect
of the region on the transcriptional activity was deter-
mined as a unit. We classified the regulatory region of
UGT1A1 with the detected polymorphisms into the fol-
lowing three regions: the TATA box includingMatsui et al. BMC Gastroenterology 2010, 10:57
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Table 1: Primers for amplification and sequencing of UGT1A
Primer name Sequence (5' to 3') Condition
Amplification of UGT1A1 transcriptional regulatory region for direct sequence
Amp1-F CACCTCCTCCTTATTCTCTTa fragment 1
Amp1-R CCTTGAATTTCCAAAATCCCAGA 3 min at 96°C, 35 cycles (20 sec at 96°C, 15 sec at 57°C, 90 sec at 
72°C), 5 min at 72°C
Amp2-F GATACAAGGCAGAACAGAAC fragment 2
Amp2-R AGGTCACACGGTTACTCTGA 2 min at 94°C, 35 cycles (20 sec at 94°C, 30 sec at 61°C, 70 sec at 
72°C), 5 min at 72°C
Amp3-F TGAGCGCTGAAAATCTCAAC fragment 3
Amp3-R AGAGAGGAAGAAGGACGACT 3 min at 94°C, 32 cycles (30 sec at 94°C, 45 sec at 59°C, 60 sec at 
72°C), 10 min at 72°C
Amp4-F ACAGGTTTCCATGGCGAAAG fragment 4
Amp4-R GCTTGCTCAGCATATATCTCTGGGb 2 min at 94°C, 35 cycles (20 sec at 94°C, 30 sec at 61°C, 60 sec at 
72°C), 5 min at 72°C
Amplification of proximal and distal regulatory regions from genome DNA for cloning
Proximal-F1 GACTGCCATCCAGTAGGGCTCACACGTT
Proximal-R1 CGCCTTTGCTCCTGCCAGAGGTTCG 2 min at 94°C, 30 cycles (20 sec at 94°C, 5 min at 68°C), 10 min at 
68°C
Distal-F1 GAGATCTGAGTTCTCTTCACCTCCTCCT
Distal-R1 GCAGAGCTTCCAAGCTTTTTGAGGCTG 2 min at 94°C, 30 cycles (20 sec at 94°C, 30 sec at 63°C, 2 min at 72°C), 
5 min at 72°C
Addition of restriction enzyme site of cloned transcriptional regulatory regions by PCR
(underline: Sac I site on Proximal-F2 and Distal-F2; Xho I site on Proximal-R2)
Proximal-F2 GAGAGCTCCCTCAGCCCCTAGAGCACCATC
Proximal-R2 CTCTCGAGGCGCCTTTGCTCCTGCCAGAGG 2 min at 94°C, 8 cycles (20 sec at 94°C, 30 sec at 60°C, 90 sec at 72°C), 
5 min at 72°C
Distal-F2 GAGAGCTCGAAGGGATTAGTTTAGGACAACCCTCCTTC
Distal-R1 GCAGAGCTTCCAAGCTTTTTGAGGCTG 2 min at 94°C, 8 cycles (20 sec at 94°C, 30 sec at 60°C, 90 sec at 72°C), 
5 min at 72°C
Sequencing primers for transcriptional regulatory region of UGT1A1
Seq1-1 TATTCTCTTTTTGACACTGG
Seq1-2 GACCAAGGTTCCAGAAGTGGTGGTGA
Seq1-3 CAATTACAGGGGATGGTGCTCTAG
Seq1-4 CTTCCAATTCTGGCTGCACA 5 min at 96°C, 25 cycles (10 sec at 96°C, 5 sec at 50°C, 4 min at 60°C) c
Seq1-5 GACGAAGGAATGAAACACAT
Amp4-F ACAGGTTTCCATGGCGAAAGMatsui et al. BMC Gastroenterology 2010, 10:57
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A(TA)7TAA, gtPBREM including c.-3275T>G, and the
remaining region with the ten linked polymorphisms,
according to their locations in the regulatory sequence
and previous studies. To study the effects of the three
regions on transcription, either solely or in combination,
vectors with different combinations of polymorphisms
were constructed by restriction and ligation, as listed in
Figure 1. Vectors Nos. 3-8 are combination types.
Construction of CAR expression vector
CAR-cDNA was isolated from a human liver cDNA
library (TaKaRa BIO INC) by PCR, as described by Auer-
bach et al [26]. The PCR product was cloned into pCR2.1
vector (Invitrogen Corporation). CAR-cDNA was cut out
by EcoR I and EcoR V, and ligated into the pCR3.1 vector
(Invitrogen Corporation).
Transfection and luciferase assay
HepG2 cells from the Riken Cell Bank (Tsukuba, Japan)
were cultured in the minimal essential medium, which
includes Earle's salts, non-essential amino acids but not -
L-Glutamine (MEM, Invitrogen Corporation), supple-
mented with 10% fetal bovine serum (Invitrogen Corpo-
ration), 50 U of penicillin/ml and 50 μg of streptomycin/
ml. The cells were transferred to a 24-well culture plate (7
× 104 cells/well) at 25 hours before transfection. For the
transfection, 250 μl of MEM, 3.0 μl of GenePORTER®
Transfection Reagent (GeneLantis, San Diego, CA) and
plasmid vectors were poured onto the cells in each well.
The composition of the plasmid vectors for transfection
w a s :  l u c i f e r a s e  r e p o r t e r  p l a s m i d  P G V - B 2  w i t h  a  t r a n -
scriptional regulatory region (400 ng), the CAR-pCR3.1
expression plasmid or mock plasmid (200 ng), and the
Renilla luciferase expression plasmid pRL-SV40 (6 ng) for
normalization. After 3 hours, 250 μl of MEM containing
20% fetal bovine serum was added to each well. After 28
hours the transfected cells in each well were lysed, and
the dual luciferase activities were immediately measured
with a PicaGene Dual SeaPansy Luminescence Kit
(TOYO B-Net CO., LTD).
Data analysis
Haplotype analysis was carried out using Haploview 3.32
software [27]. Changes in transcriptional activity due to
the polymorphisms were analyzed by multiple regression
analysis (see Additional file 1, Table S1), using
SPSS16.0.1J software (SPSS Japan Inc., Tokyo, Japan). For
dummy coding, we defined the wild-type and mutant-
type polymorphisms as 0 and 1, respectively.
Results
Sequencing and haplotype analysis in the regulatory 
region of UGT1A1
The upstream region of UGT1A1  was analyzed in
patients with Gilbert syndrome and in normal Japanese
and Caucasian subjects. The regulatory region of wild
type was consistent with NG_002601, which is stated to
be the sequence of UGT1A1 by the US National Center
for Biotechnology Information (Table 2, type I). Fourteen
polymorphic variations with distinct combinations were
identified (T able 2). A(T A)7T AA always linked with c.-
3275T>G, c.-2951A>G, c.-2743T>C, c.-2726G>A, c.-
2473T>G, c.-1352A>C, c.-689A>C and c.-364C>T. In
addition, the alleles with A(TA)7TAA had variants of the
AT-repeat number from c.-2724. The AT-repeat number
at c.-2724 of the wild type was three; we denote this as c.-
2724AT [3]. The variant of Japanese patients having
homozygous A(TA)7TAA was eight AT-repeats: c.-
2724AT[8]. The repeat number was greater than eight in
Caucasian patients, but could not be determined exactly
because of the difficulty involved in reliable amplification
w i t h  P C R .  T h e s e  v a r i a n t s  a r e  d e s c r i b e d  h e r e  a s  c . -
2724AT[>8]. Also, A(TA)7TAA was linked mostly with
Sequencing primers for cloned transcriptional regulatory regions
Seq2-1 TCTGCTGTTGGCTGAATCTG
Seq2-2 TATACACACGGCCTGCAAGT
Seq2-3 CAGAATGGCTAGAGGGTAAG
Seq2-4 ACAGAAACATGTCCAGAGCACTT
Seq2-5 TGTCTGATGGTGGCCTACTA
Seq2-6 TTGCTGCCCTGCTGTGTG 5 min at 96°C, 25 cycles (10 sec at 96°C, 5 sec at 50°C, 4 min at 60°C) c
Seq2-7 CATCCAGGTACACAGCAGAA
Seq2-8 TCATTCCACTGGCCCAAGAT
Seq2-9 GGTTCCCAATCAGGTCCATT
Seq2-10 TCACATGCGCTCCAGTGAAT
Seq1-2, Seq1-4, Amp4-F
aSugatani et al. [10]bMaruo et al. [15]cYamada et al. [35]
Table 1: Primers for amplification and sequencing of UGT1A (Continued)Matsui et al. BMC Gastroenterology 2010, 10:57
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c.-3152G>A (c.-3156G>A in a previous report (10)) and
c.-2737T>C. From the analysis, nine different haplotypes
were identified, with distinct combinations of the 14
polymorphic variations (Table 2) and 14 kinds of diplo-
type (see Additional file 2, Table S2).
Effect of regulatory polymorphisms on transcription
Based on haplotype analysis of Gilbert patients in Japa-
nese and Caucasians, we selected the most typical regula-
tory regions of wild and Gilbert -syndrome type for in-
vitro expression studies: in Table 2, type I and type V
respectively. The regulatory region for Gilbert syndrome
was cloned from a Japanese patient because of the uncer-
tain number of AT-repeat in Caucasians, since all
homozygotes with A(TA)7TAA were Gilbert syndrome
irrespective of c.-2724AT[8] or c.-2724AT[>8]. To sim-
plify the analysis, the regulatory region with the detected
polymorphisms was classified into three categories: the
TATA box including A(TA)7TAA; gtPBREM including c.-
3275T>G; and the region with the ten linked polymor-
phisms specified in the Materials and Methods section
above.
The gray bars in Figure 2 show transcriptional activities
without co-expression of CAR. A(TA)7TAA did not sig-
nificantly reduce transcriptional activity (94% of wild
type,  p  = 0.14). In contrast, c.-3275T>G and the ten
linked polymorphisms significantly reduced the activity,
to 69% and 88% of wild type respectively (p < 0.001 and p
= 0.001). Our study shows that c.-3275T>G exerts the
greatest reduction in transcription. The typical haplotype
o f  G i l b e r t  p a t i e n t s  ( G - m - ( T A ) 7 _ G i l b e r t  i n  F i g u r e  2 )
reduced transcriptional activity to 56% of wild type.
The white bars in Figure 2 show transcriptional activi-
ties with co-expression of CAR. The activity of wild-type
haplotype was increased with CAR by a factor of 4.27
(S.D. = 0.18, p < 0.001). The ten linked polymorphisms
alone did not reduce transcriptional activity. In contrast,
c.-3275T>G and A(TA)7TAA significantly reduced the
activity, to 85% and 83% of wild type respectively (p <
0.001 and p < 0.001). The typical haplotype of Gilbert
syndrome patients (G-m-(TA)7_Gilbert in Figure 2)
reduced transcriptional activity to 68% of wild type.
These results suggest that AT(TA)7TAA by itself does not
reduce transcriptional activity enough to cause Gilbert
syndrome, and that co-operation of c.-3275T>G and the
ten linked polymorphisms with AT(TA)7TAA is neces-
sary to cause the syndrome.
Discussion
By reducing the transcription of UGT1A1, A(TA)7TAA is
acknowledged to be one of the most important causes of
Gilbert syndrome. Further polymorphisms located
upstream of the UGT1A1-coding region have recently
been detected but, apart from A(TA)7TAA and -
3275T>G at gtPBREM, the role of these polymorphisms
in the development of Gilbert syndrome is currently
unclear.
In the present analysis of the regulatory region of
UGT1A1, nine haplotypes were detected with differing
combinations of 14 polymorphic variations (Table 2).
From this analysis we were able to determine the typical
haplotype of the regulatory region of patients with
A(TA)7TAA as c.-3275G,.c-3152A, c.-2951G, c.-2743C,
c.-2737C, c.-2726A, c.-2724AT[8] or [>8], c.-2473G, c.-
1352C, c.-1125C, c.-997G, c.-689C, c.-364T and
A(TA)7TAA. In addition, the regulatory region of wild
type was identical with NG_002601 in all Japanese and
Caucasian cases, and different from the sequence used in
previous expression studies, namely AF297093 in Gen-
Bank [12,28]. Specifically, four base-pairs (c.-3043T, c.-
3032G, c.-2985C and c.-2982G) downstream near gtP-
BREM in AF297093 do not exist in NG_002601.
We classified the regulatory region into three catego-
ries so as to simplify the analysis, taking account of previ-
ous studies and the locations found in the regulatory
sequence. Those three categories are: gtPBREM includ-
Figure 1 List of vectors constructed. UGT1A1 regulatory regions (c.-
4076 to c.-1, Nos. 1 - 8), with differing combinations of polymorphic 
variations, were inserted into the luciferase reporter plasmid PGV-B2. 
The wild-type vector is No.1, and No.2 is a typical vector with regulato-
ry regions showing Gilbert syndrome. The open box is a wild-type re-
gion between gtPBREM and the TATA box, including ten linked 
polymorphisms: c.-3152G>A, c.-2951A>G, c.-2743T>C, c.-2737T>C, c.-
2726G>A, c.-2724AT[8], c.-2473T>G, c.-1352A>C, c.-689A>C and c.-
364C>T. The gray box is a mutant-type region having mutant-type se-
quence corresponding to the wild-type region. Luc is luciferase cDNA. 
The name of the expression vector corresponds to the polymorphisms 
included and the type of vector. In the first part of the name, T and G 
respectively denote c.-3275T and c.-3275G. In the second part of the 
name, w and m refer to wild type and mutant-type region between gt-
PBREM and the TATA box. In the third part, (TA)6 and (TA)7 denote 
A(TA)6TAA and A(TA)7TAA. In the fourth part, wild, Gilbert and combi-
nation indicate that each vector has wild-type sequence, or typical mu-
tant-type sequence in subjects suffering from Gilbert syndrome, or an 
artificial sequence constructed for this study.
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Table 2: Haplotypes in the UGT1A1 transcriptional regulatory region
type Number of allele gtPBREM Polymorphisms in the region between gtPBREM and TATA box TATA box
JRSa
(100) e
JG7b
(8) e
NCc
(20) e
CGd
(22)e
-3275 -3152 -2951 -2743 -2737 2726 -2724AT[n] -2473 -1352 -1125 -997 -689 -364 A(TA)nTAA
Haplotypes with A(TA)6TAA
I 6 801 10 T G A T T G 3 T A C G A C 6
II 19 0 4 0 G GATTA> 8G C C ACC6
I I I 0010 TG A T T G 3 GCC ACC6
I V 2000 TG A T T G 3 T C C A AC 6
Haplotypes with A(TA)7TAA
V1 0 8 0 0 GA * G * C * C * A * 8 * G * C * CG C* T* 7
VI 1 0 3 12 GA G C C A> 8 G C CGCT 7
VII 0 0 1 5 G G GCT A> 8G C CGCT 7
V I I I 0004 G G GCCA > 8 GCTG CT 7
I X 0001 GA G C C A> 8 G C T G CT 7
Boldfaces indicate variations.
aJRS, Japanese random subjects; bJG7, Japanese patients with Gilbert syndrome having homozygous A(TA)7TAA; cNC, normal Caucasians; dCG, Caucasian patients with Gilbert syndrome; 
eNumbers in parentheses indicate the number of total alleles in each group
*Ten linked polymorphisms between gtPBREM and TATA boxMatsui et al. BMC Gastroenterology 2010, 10:57
http://www.biomedcentral.com/1471-230X/10/57
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ing c.-3275T>G; the region including ten linked polymor-
phisms; and the TATA box including A(TA)7TAA. We
further examined their effect on transcription, both in
the presence and absence of CAR. This was done for
three reasons. First, enhancer activity of gtPBREM is ele-
vated by CAR in in-vitro experiments using culture cells
[10]. Second, CAR has been proposed as a key regulator
of bilirubin clearance in the liver in wild type and human-
ized CAR transgenic mice [29]. Third, c.-3275T>G is
reported to be a further factor for the development of
hyperbilirubinemia [30].
Transcription of the wild-type regulatory region was
enhanced 4.3 times by co-expression of CAR (Figure 2).
This was a similar factor to that in previous studies of
UGT1A1 [10]. There were differences in transcription
between A(TA)7TAA, c.-3275T>G and the ten linked
polymorphisms, both in the presence and the absence of
CAR. A(TA)7TAA by itself reduced transcription to 94%
of wild type (p = 0.14, not significant) without CAR, and
to 83% (p < 0.001) with CAR. By itself, then, A(TA)7TAA
does not reduce transcriptional activity to 42-50%, which
is the value estimated from the enzyme activity and the
amount of enzyme protein in human liver samples of
homozygous A(TA)7TAA [18-20]. A(TA)7TAA likewise
does not reduce transcription down to the values found
in human samples in our experiment using shorter regu-
latory regions (c.-2323 to c.-1 and c.-274 to c.-1) (data not
shown). These results suggest that further mutations/
variations linked to A(TA)7TAA participate in reducing
the transcription.
The ten linked polymorphisms located between
A(TA)7TAA and c.-3275T>G together reduced tran-
scription to 88% (p = 0.001) of wild type without CAR.
This reduction might be due mainly to c.-1352A>C, since
this variation reduced the activity to 85% of wild type in
our previous study with a 3-kbp regulatory region [21].
The ten linked polymorphisms did not induce any signifi-
cant change in transcription with CAR. It is not clear why
there was no significant reduction of transcription in the
presence of CAR, but the 4.3-fold enhancement of the
activity with CAR might mask the inhibitory effect of c.-
1352A>C.
Unlike A(TA)7TAA and the ten linked polymorphisms,
c.-3275T>G noticeably reduced transcriptional activity
both with and without CAR, to 69% (p < 0.001) and 85%
(p < 0.001) of wild type respectively. This result is consis-
tent with the report that c.-3275T>G is a factor for the
development of hyperbilirubinemia [30].
S u g a t a n i  e t  a l .  r e c e n t l y  r e p o r t e d  t h a t  t h e  T A T A  b o x
reduced transcription to a greater extent than c.-
3275T>G (c.-3279T>G on their sequence), in a study
using the regulatory region from c.-3570 to c.-1 [28]. This
regulatory region has two significant differences in their
work and ours. First, they did not consider the ten poly-
morphisms between gtPBREM and the TATA box. Sec-
ond, their study used the sequence of AF297093 whereas
we used NG_002601. At least part of the discrepancy
between their results and ours might stem from these dif-
ferences.
Without CAR, the typical haplotype of Gilbert syn-
drome patients was effective in reducing transcription, to
56% of wild type, and with CAR to 68% of wild type (Fig-
ure 2). The results without CAR are almost compatible
with previous in vivo data: UGT1A1 enzyme activity was
48%, and the expression level of UGT1A1 protein was 42-
50%, of wild type in studies using human liver samples of
carriers with homozygous A(TA)7TAA [18-20]. There is
only a small amount of CAR in the nuclei of human pri-
mary hepatocytes [31], but it has been reported that
defects in bilirubin clearance are not observed in CAR-
null mice until the appropriate stress is applied, and that
nuclear CAR increases in the presence of activators such
Figure 2 Transcriptional activity of the continuous 4-kbp regula-
tory region (c.-4076 to c.-1) with/without the CAR expression 
plasmid. The combination of variations in each expression vector is 
shown in Figure 1. Name of expression vector represents polymor-
phisms included and vector type. In the first part of the name, T and G 
respectively denote c.-3275T and c.-3275G. In the second part of the 
name, w and m refer to wild type and mutant-type region between gt-
PBREM and the TATA box. In the third part, (TA)6 and (TA)7 denote 
A(TA)6TAA and A(TA)7TAA. In the fourth part, wild, Gilbert and combi-
nation indicate that each vector has wild-type sequence, or typical mu-
tant-type sequence in subjects suffering from Gilbert syndrome, or an 
artificial sequence constructed for this study. The mean transcriptional 
activity of the wild-type vector, T-w-(TA)6_wild, without the CAR ex-
pression plasmid was chosen as 1.00. Each column and bar represents 
the mean and SD of four independent determinations. The vector with 
typical regulatory region showing Gilbert syndrome is G-m-
(TA)7_Gilbert. The open box is a wild-type region between gtPBREM 
and the TATA box, including ten linked polymorphisms: c.-3152G>A, 
c.-2951A>G, c.-2743T>C, c.-2737T>C, c.-2726G>A, c.-2724AT[8], c.-
2473T>G, c.-1352A>C, c.-689A>C and c.-364C>T. The gray box is a mu-
tant-type region having mutant-type sequence corresponding to the 
wild-type inner region. Luc is luciferase cDNA.
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as a large concentration of bilirubin [29]. Consequently
the CAR state of the patients may be similar to those in
the experiment without CAR, in which case CAR is not
important to serum bilirubin levels of the patient. Even if
the amount of nuclear CAR in the patients is intermedi-
ate between the values in the experiments with and with-
out CAR, A(TA)7TAA by itself is not enough to reduce
transcription to the level found in the liver of patients
with homozygous A(TA)7TAA [18-20].
Bilirubin levels are found to be related to polymor-
phisms of UGT1A1; c.-3275T>G, A(TA)7TAA and
c.211G>A in epidemiological genetic studies [30,32].
Epidemiological evaluation of the effect of each poly-
morphism on the development of Gilbert syndrome is
difficult, because almost all haplotypes with A(TA)7TAA
also have c.-3275T>G and other polymorphisms such as
c.-1352A>C.
Our in-vitro studies imply the existence of combined
effects of the polymorphisms on transcriptional activity
in the development of Gilbert syndrome; these studies
use vectors with combinations of the polymorphisms
designed specifically to analyze the role of the individual
polymorphisms. Our results may explain why almost all
patients with Gilbert syndrome are double homozygous
for A(TA)7TAA and c.-3275T>G [24,33,34]. Since c.-
3275T>G alone is not enough to reduce the transcription
leve l t o tha t of t he pa tients, less fr equent A(T A)7T AA
may play a determinant role in the etiology of Gilbert
syndrome. Exceptional patients, such as one who is
homozygous for A(TA)7TAA and heterozygous for c.-
3275T>G, heterozygous for A(TA)7TAA and homozy-
gous for c.-3275T>G, and homozygous only for c.-
3275T>G, may have further variations of UGT1A1 that
have not yet been investigated, or have variations of the
other enzyme(s) related to bilirubin metabolism
[28,33,34]. Further studies of the relation between serum
bilirubin concentration and genotype that include
enough patients with minor haplotypes, based on this
analysis, should identify accurately the involvement of
each polymorphic mutation in the development of Gil-
bert syndrome.
Conclusions
All haplotypes of Gilbert syndrome patients with
A(TA)7TAA have both c.-3275T>G and 8-11 polymor-
phisms between gtPBREM and A(TA)7TAA. CAR
increases transcription and changes the amount of inhibi-
t i o n  e x e r t e d  b y  e a c h  p o l y m o r p h i s m  o n  t r a n s c r i p t i o n .
Regardless of the presence of CAR, A(TA)7TAA did not
by itself reduce transcriptional activity enough to cause
Gilbert syndrome. Our study shows that c.-3275T>G and
the ten polymorphisms detected in the patients are also
important for the decrease of transcription of UGT1A1 in
addition to A(TA)7TAA, and that Gilbert syndrome is
likely to be caused by the combined effects of these poly-
morphisms.
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